Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.
Overview
Perrigo Company Plc (PRGO) is a foremost global provider of over-the-counter consumer self-care products and affordable health solutions. With roots dating back to 1887, the company has evolved from packaging generic home remedies to a focused, pure-play consumer self-care business, specializing in a wide range of products from infant formulas to branded over-the-counter healthcare solutions.
Core Business and Product Portfolio
Perrigo operates across a spectrum of product categories that include store brand offerings and nationally recognized branded products. Its portfolio covers key segments such as infant formula for store brands, branded OTC products, and innovative health solutions like its pioneering over-the-counter daily birth control pill. With a robust blend of store brand and national brands, Perrigo’s business model is anchored on providing quality, accessible healthcare options that empower individuals to manage minor health conditions effectively.
Market Position and Global Presence
Positioned as one of the largest consumer health companies, Perrigo’s operations extend primarily across North America, Europe, Australia, and strategic markets in Asia and the Middle East. Its extensive distribution network includes major retailers such as Walmart, Amazon, Costco, and CVS, underscoring a resilient and expansive market reach. The company’s commitment to 'quality affordable healthcare products' is reflected in its tailored approach to meet diverse consumer needs, offering products that blend trusted efficacy with competitive pricing.
Business Model and Strategic Initiatives
Perrigo’s revenue is driven by a well-diversified product mix that leverages both private-label and branded offerings. Its transformation into a pure-play consumer self-care company was achieved through strategic divestments in areas such as animal health and generic pharmaceuticals, allowing a sharper focus on consumer self-care. The integrated business model maximizes profitability by reinvesting savings through operational efficiency programs and strengthening high-growth segments. Initiatives aimed at innovation and operational streamlining, such as the globally recognized Project Energize, underscore its commitment to maintaining competitive cost structures and enhancing product margins.
Innovation and Consumer-Focused Strategy
Innovation remains a cornerstone of Perrigo’s strategy. The company continuously invests in new product launches and refinements that align with evolving consumer needs and regulatory changes. Its recent advancements in the reproductive health space—exemplified by partnerships that enhance health education and access—demonstrate a commitment to addressing critical areas of consumer well-being. Such initiatives not only reinforce brand strength but also contribute to market differentiation within the competitive landscape of OTC health and wellness solutions.
Industry Expertise and Differentiation
Perrigo’s long-established presence and expertise in the consumer health arena are backed by decades of operational excellence and strategic leadership. The company’s ability to consistently deliver high-quality, affordable products positions it uniquely among its peers. Detailed management succession plans and operational transitions further exemplify its robust internal expertise and focus on sustaining long-term value creation. By harnessing a blended-branded approach, Perrigo successfully addresses various consumer demographics, ensuring accessibility to essential health products across multiple price points.
Conclusion
Overall, Perrigo Company Plc remains an influential force in the global consumer self-care market. Its commitment to quality, affordability, and continuous innovation serves as a testament to its proven business model. For investors and market analysts alike, Perrigo offers a comprehensive case study in achieving market resilience and operational excellence in a rapidly evolving healthcare landscape.
Perrigo Company plc (NYSE: PRGO) will release its third quarter 2022 financial results on November 8, 2022, at 8:30 A.M. (EST). A conference call will follow, available via webcast on the investor relations section of the Perrigo website or by phone. The replay of the call will be accessible from November 8 at 12:00 P.M. until November 15. Perrigo is a leading provider of Consumer Self-Care Products that empower consumers to manage their health independently.
Perrigo Company plc (NYSE: PRGO) announced that the FDA will hold a joint meeting on November 18, 2022, to review its application for Opill®, a daily oral contraceptive, for over-the-counter (OTC) use. This could mark Opill® as the first daily birth control pill available OTC in the U.S. The application was filed by Perrigo's affiliate, HRA Pharma. However, the outcome of the FDA's review remains uncertain, and there are risks associated with regulatory approval.
Perrigo Company plc (NYSE: PRGO) addressed recent misleading commentary regarding the ranitidine (Zantac) litigation. On August 4, 2022, Perrigo was dismissed from the Bayer v. Boehringer Ingelheim case, which barred re-filing claims against them. The company clarified that litigation claims against it were misrepresented. Perrigo maintains strong defenses against these claims, supported by scientific evidence negating a cancer link. The company has successfully dismissed numerous related cases and remains committed to defending against all unfounded claims.
Perrigo reported second-quarter 2022 net sales of $1.1 billion, a 14.3% increase year-over-year, or 20.2% excluding currency impacts. Organic net sales rose 17.2%, driven by strong demand for consumer self-care products. Gross margins reported at 33.2%, with adjusted gross margins at 36.5%. Despite a reported net loss of ($0.48) per diluted share, adjusted EPS was $0.43. Perrigo raised its fiscal 2022 organic growth guidance to 9.0%-10.0% but updated adjusted EPS outlook to $2.25-$2.35 due to currency translation challenges.
Perrigo Company plc (NYSE: PRGO) declared a quarterly dividend of $0.26 per share, scheduled for payment on September 20, 2022. Shareholders on record as of September 2, 2022 will be eligible. This announcement reflects the company's commitment to providing shareholder returns amidst a challenging market environment.
Perrigo offers a range of Consumer Self-Care Products and aims to empower consumers in managing their wellness proactively.
Perrigo Company plc (NYSE: PRGO) is set to release its second quarter 2022 financial results on August 9, 2022, with a conference call scheduled for 8:30 A.M. EDT. The call will be accessible via webcast on the investor relations section of the Perrigo website. A replay will be available shortly after the call until August 16, 2022.
Perrigo is a leading provider of Consumer Self-Care Products and OTC health solutions, focusing on enhancing individual well-being.
Perrigo Company plc (NYSE: PRGO) announced that HRA Pharma has submitted an application to the FDA for the first-ever over-the-counter birth control pill, Opill®. This progestin-only pill aims to increase contraceptive access in the U.S., potentially reducing the high rate of unintended pregnancies, which number over 6.1 million annually. Major medical organizations support this initiative, underscoring its significance in reproductive health. If approved, Opill® would be the first OTC daily birth control pill available without a prescription in the U.S.
Perrigo Company plc (NYSE: PRGO) has appointed Ms. Alison Ives as Executive Vice President and Chief Scientific Officer. Ms. Ives will oversee global research and development and regulatory efforts, joining the Company’s Operating Committee. CEO Murray S. Kessler emphasized her 20 years of experience, highlighting her role in enhancing Perrigo's product portfolio, which now has over $500 million in potential revenue. Ms. Ives expressed confidence in delivering innovation with her team at Perrigo, reinforcing the company's commitment to consumer self-care.
Perrigo Company plc (NYSE: PRGO) announced that President and CEO Murray S. Kessler and CFO Eduardo Bezerra will engage in investor meetings at the Credit Suisse HALO Investment Summit in New York City on May 25, 2022, with no formal presentation planned.
Kessler is also set to virtually present at the Oppenheimer Consumer Growth and E-Commerce Conference on June 15, 2022, at 9:45 AM EDT. Interested parties can access webcasts via the Perrigo website. Perrigo is a leading provider of consumer self-care products, ranking as the largest store brand OTC player in the U.S.
Perrigo reported first quarter 2022 net sales of $1.1 billion, reflecting a 6.4% increase from the previous year, with organic growth at 9.7%. The loss per diluted share was $0.01, compared to an earnings per share of $0.02 last year. Adjusted diluted EPS dropped to $0.33 from $0.50, impacted by cost headwinds and foreign exchange fluctuations. The acquisition of HRA Pharma bolstered sales expectations, prompting an increase in fiscal 2022 net sales growth guidance to 8.5%-9.5% from 3.5%-4.5%.
FAQ
What is the current stock price of Perrigo Co Plc (PRGO)?
What is the market cap of Perrigo Co Plc (PRGO)?
What products does Perrigo offer?
How has Perrigo evolved over the years?
What is Perrigo's core business model?
Which markets are key to Perrigo's global presence?
How does Perrigo differentiate itself from competitors?
What recent innovations has Perrigo introduced?
How does Perrigo maintain its commitment to affordable healthcare?
What strategic initiatives support Perrigo's business transformation?
